American Society of Hirudotherapy

The efficacy and safety of direct oral anticoagulants in the treatment of the acute phase of heparin-induced thrombocytopenia: A systematic review

Review published in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2024)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Systematic reviewClinical LiteratureDrug DevelopmentSadowski et al. · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2024

Abstract

PURPOSE: To investigate the safety and efficacy of direct oral anticoagulants (DOACs) in the treatment of the acute phase of heparin-induced thrombocytopenia (HIT). SUMMARY: A systematic review of the literature was conducted on PubMed, MEDLINE, Embase, and Web of Science Core Collection through July 2023. Search terms included "heparin-induced thrombocytopenia AND direct-oral-anticoagulants" in addition to a list of oral anticoagulants. Adult patients who used direct oral anticoagulants as the initial treatment for the acute phase of HIT were included. A total of 1,188 articles were initially identified, with 770 articles reviewed following removal of duplicates. Following the application of inclusion and exclusion criteria, 12 articles were ultimately included. Rivaroxaban was the most-utilized DOAC (28 patients), followed by apixaban (7 patients) and dabigatran (1 patient). All patients with thrombocytopenia demonstrated successful platelet recovery, with two patients presenting with normal platelet counts. One patient developed a deep venous thrombosis with no other new or recurrent thromboses. There were no reported clinically significant adverse events in any patient. Obstacles and deterrents to the use of the standards of care in the acute phase of HIT exist. Argatroban and bivalirudin require intravenous infusion and require close aPTT monitoring and dose adjustment. Fondaparinux requires injection and is contraindicated with body weight <50kg. DOACs would offer the novel ability for an oral treatment in the treatment of the acute phase HIT and allow for minimal monitoring and consistent dosing strategies. Therefore, DOACs are an intriguing choice for the treatment of the acute phase of HIT. CONCLUSION: Data from 12 publications and across 36 patients suggests that the use of DOACs in the acute phase of HIT may be a safe and efficacious treatment option with favorable ease of monitoring and management.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeSystematic ReviewJournal Article
Indexed MeSH termsHumansThrombocytopeniaHeparinAnticoagulantsAdministration, OralAcute DiseaseTreatment OutcomePyridonesRivaroxabanPyrazoles

Summary

This systematic review of 12 publications (36 patients) found that DOACs used first-line in acute HIT—mostly rivaroxaban (28 patients), then apixaban (7) and dabigatran (1)—achieved platelet recovery with one deep vein thrombosis and no clinically significant adverse events.

Why This Matters for Hirudotherapy

This systematic review evaluated direct oral anticoagulants (DOACs)—primarily rivaroxaban (28 patients), apixaban (7), and dabigatran (1)—as initial treatment for the acute phase of heparin-induced thrombocytopenia (HIT), pooling data from 36 patients across 12 publications. All patients with thrombocytopenia demonstrated successful platelet recovery, with one patient developing deep venous thrombosis and no clinically significant adverse events reported. The review mentions bivalirudin as a current standard-of-care option requiring intravenous infusion and close monitoring, but makes no reference to hirudin, leeches, or leech-derived compounds. Caveat: The small aggregate sample (36 patients) limits the strength of these findings, and the review notes obstacles to current standards of care. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.

Citation

Reference (Vancouver style)

Sadowski C, Reinert JP. The efficacy and safety of direct oral anticoagulants in the treatment of the acute phase of heparin-induced thrombocytopenia: A systematic review. Am J Health Syst Pharm. 2024;81(19):e584-e593. doi:10.1093/ajhp/zxae109. PMID: 38651828

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.